Loading...
XNAS
PVLA
Market cap199mUSD
Jul 09, Last price  
151.04USD
1D
4.03%
1Q
18.82%
Jan 2017
34.36%
IPO
-33.75%
Name

Pieris Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:PVLA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
75.23%
Rev. gr., 5y
8.03%
Revenues
0k
11,383,3229,879,9105,365,0542,931,9315,830,67425,275,00029,101,00046,279,00029,323,00031,418,00025,902,000000
Net income
-42m
L+139.27%
-2,320,54666,196-9,849,964-14,058,641-22,799,164-17,647,000-26,754,000-23,755,000-37,230,000-45,738,000-33,277,00018,691,000-17,434,000-41,715,000
CFO
-25m
L+130.68%
-9,087,479-3,076,482-5,065,701-12,705,480-14,387,93449,754,000-1,066,000-52,467,000-45,896,000-7,660,000-14,840,000-13,703,000-10,840,000-25,006,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
URL
https://www.pieris.com/
IPO date
Dec 18, 2014
Employees
127
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT